Evidence map›Paper›PMID 41073843›Full record

Observational studyNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2025

Efficacy and safety of branded vs generic lacosamide in epilepsy: a retrospective real-world study.

Giuseppe Salafica, Diana Tilenni, Attilio Vinaccia, Giovanni Tripepi, Chiara Martellino, Salvatore Maria Lima, Giorgia Atanasio, Fabio Lamanna, Orazio Pardeo, Mariangela Panebianco and 2 more

Abstract readObservational StudyMulticenter StudyComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Giuseppe SalaficaNeurophysiopatology and Movement Disorders Clinic, Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy.
Diana TilenniNeurophysiopatology and Movement Disorders Clinic, Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy.
Attilio VinacciaNeurophysiopatology and Movement Disorders Clinic, Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy.
Giovanni TripepiNational Research Council (CNR), Institute of Clinical Physiology (IFC), Clinical Epidemiology of Renal Diseases and Hypertension, Ospedali Riuniti, Reggio Calabria, Italy.
Chiara MartellinoNeurophysiopatology and Movement Disorders Clinic, Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy.
Salvatore Maria LimaDepartment of Biomedicine, Neuroscience, and Advanced Diagnostic (BIND), University of Palermo, Palermo, Italy.
Giorgia AtanasioNeurophysiopatology and Movement Disorders Clinic, Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy.
Fabio LamannaNeurophysiopatology and Movement Disorders Clinic, Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy.
Orazio PardeoNeurophysiopatology and Movement Disorders Clinic, Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy.
Mariangela PanebiancoNeurology and Stroke Unit-ARNAS Garibaldi, Catania, Italy.
Angelina LaganàNeurophysiopatology and Movement Disorders Clinic, Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy.
Angelo LabateNeurology Clinic, University of Palermo, Palermo, Italy. labate270273@gmail.com.ORCID http://orcid.org/0000-0002-8827-7324

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeLacosamide (LCS) is a third-generation antiseizure medication (ASM) approved for focal-onset seizures and generalized epilepsy. Although the branded formulation, Vimpat

methodsA multicenter, retrospective, observational study was conducted at two epilepsy centers in Southern Italy. Sixty adult patients were included and divided into two groups: Group A (n = 30) received branded LCS and Group B (n = 30) received the generic formulation. Data were collected at treatment initiation (T0) and the first follow-up (T1), including seizure frequency, adverse events and dose adjustments. The primary outcome was the responder rate (≥ 50% reduction in seizure frequency), with secondary outcomes including seizure freedom, adverse events and dose changes.

resultsBaseline characteristics were similar between groups. The average daily LCS dose was significantly higher in the Vimpat

conclusionsIn this real-world setting, generic LCS (Stutan

Indexed as

AnticonvulsantsDrugs, GenericEpilepsies, PartialEpilepsyLacosamideAdultAgedFemaleHumansItalyMaleMiddle AgedRetrospective StudiesTreatment OutcomeYoung AdultAnticonvulsantsDrugs, GenericLacosamideEpilepsyGeneric formulationLacosamideReal-world study

Identifiers

PMID41073843
PMCPMC12678553

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.